DexCom, Inc. (DXCM) EV/FCF Ratio: 21.01x
Is DexCom, Inc.’s EV/FCF ratio high or low?
DexCom, Inc.'s EV/FCF ratio of 21.01x is 88% below its 5-year average of 181.62x, near the low end of its 5-year range (16.11x–988.12x).
The EV/FCF ratio for DexCom, Inc. (DXCM) is 21.01x as of Wednesday, June 10, 2026. It is below its 12-month average by 43.90% (37.45x).
DXCM EV/FCF Ratio Chart
DXCM Average EV/FCF Ratio Chart
DXCM Current vs Average EV/FCF Ratio Chart
DXCM EV/FCF Ratio Metrics
EV/FCF RATIO
21.01x
EV/FCF RATIO AVG TTM
37.45x
EV/FCF RATIO AVG 3Y
66.82x
EV/FCF RATIO AVG 5Y
181.62x
EV/FCF RATIO AVG 10Y
518.55x
EV/FCF RATIO AVG 15Y
520.67x
EV/FCF RATIO AVG 20Y
520.67x
CURRENT VS TTM AVG
-43.90%
CURRENT VS 3Y AVG
-68.56%
CURRENT VS 5Y AVG
-88.43%
CURRENT VS 10Y AVG
-95.95%
CURRENT VS 15Y AVG
-95.96%
CURRENT VS 20Y AVG
-95.96%
DXCM Competitors' EV/FCF Ratio
| NAME | MARKET CAP | EV/FCF RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| DexCom, Inc. (DXCM) | $29.24B | 21.01x | 37.45x | 66.82x | 181.62x |
| Biogen Inc. (BIIB) | $29.00B | 12.34x | 12.71x | 21.65x | 21.18x |
| IQVIA Holdings Inc. (IQV) | $30.60B | 11.70x | 19.22x | 27.05x | 27.70x |
| Medline Inc. (MDLN) | $30.90B | 26.55x | 27.74x | 27.74x | 27.74x |
| Veeva Systems Inc. (VEEV) | $26.73B | 48.97x | 29.32x | 32.91x | 38.27x |
| Centene Corporation (CNC) | $31.94B | 4.28x | 9.68x | 24.78x | 19.04x |
| Zoetis Inc. (ZTS) | $34.20B | 19.54x | 28.16x | 42.02x | 48.27x |
| Waters Corporation (WAT) | $23.83B | 133.18x | 43.36x | 43.04x | 41.43x |
| Mettler-Toledo International Inc. (MTD) | $22.85B | 31.65x | 33.77x | 33.51x | 38.38x |
| BioNTech SE (BNTX) | $21.81B | 7.13x | 22.05x | 6.21x | 11.27x |
Cash Flow Valuation Comparison
EV/FCF
21.0x
P/FCF
20.8x
FCF Yield
4.80%
Formula: EV/FCF = Enterprise Value / Free Cash Flow
EV/FCF vs P/FCF:
- EV/FCF accounts for debt and cash through enterprise value
- P/FCF only considers equity value
- EV/FCF can be compared across companies with different debt levels
- Both measure how the market values cash generation
DexCom, Inc. EV/FCF Ratio Formula & Definition
EV/FCF = Enterprise Value / Free Cash Flow (TTM)
Enterprise value to free cash flow compares total company value to the cash the business generates after capital expenditures.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
DexCom, Inc. EV/FCF Ratio FAQ
- What is the EV/FCF ratio for DexCom, Inc. (DXCM)?
- The EV/FCF ratio for DXCM stock is 21.01x.
- Is DexCom, Inc.'s EV/FCF ratio high or low?
- DexCom, Inc.'s EV/FCF ratio of 21.01x is 88% below its 5-year average of 181.62x, near the low end of its 5-year range (16.11x–988.12x).
- What is the TTM average EV/FCF ratio for DexCom, Inc. (DXCM)?
- The TTM average EV/FCF ratio for DXCM stock is 37.45x.
- What is the 3Y average EV/FCF ratio for DexCom, Inc. (DXCM)?
- The 3Y average EV/FCF ratio for DXCM stock is 66.82x.
- What is the 5Y average EV/FCF ratio for DexCom, Inc. (DXCM)?
- The 5Y average EV/FCF ratio for DXCM stock is 181.62x.
- What is the 10Y average EV/FCF ratio for DexCom, Inc. (DXCM)?
- The 10Y average EV/FCF ratio for DXCM stock is 518.55x.
- What is the 15Y average EV/FCF ratio for DexCom, Inc. (DXCM)?
- The 15Y average EV/FCF ratio for DXCM stock is 520.67x.
- What is the 20Y average EV/FCF ratio for DexCom, Inc. (DXCM)?
- The 20Y average EV/FCF ratio for DXCM stock is 520.67x.
DexCom, Inc. EV/FCF Ratio History
| DATE | EV/FCF RATIO |
|---|---|
| 2026-06-10 | 21.01x |
| 2026-06-09 | 21.72x |
| 2026-06-08 | 21.28x |
| 2026-06-05 | 20.25x |
| 2026-06-04 | 20.17x |
| 2026-06-03 | 20.22x |
| 2026-06-02 | 20.41x |
| 2026-06-01 | 20.80x |
| 2026-05-29 | 20.49x |
| 2026-05-28 | 20.11x |
| 2026-05-27 | 19.53x |
| 2026-05-26 | 20.02x |
| 2026-05-22 | 20.04x |
| 2026-05-21 | 19.98x |
| 2026-05-20 | 19.86x |
| 2026-05-19 | 18.62x |
| 2026-05-18 | 18.11x |
| 2026-05-15 | 17.16x |
| 2026-05-14 | 16.11x |
| 2026-05-13 | 16.31x |
| 2026-05-12 | 17.02x |
| 2026-05-11 | 16.52x |
| 2026-05-08 | 16.88x |
| 2026-05-07 | 16.96x |
| 2026-05-06 | 16.81x |
| 2026-05-05 | 16.56x |
| 2026-05-04 | 16.72x |
| 2026-05-01 | 17.08x |
| 2026-04-30 | 16.58x |
| 2026-04-29 | 21.75x |
| 2026-04-28 | 22.41x |
| 2026-04-27 | 23.18x |
| 2026-04-24 | 23.24x |
| 2026-04-23 | 23.66x |
| 2026-04-22 | 23.92x |
| 2026-04-21 | 23.62x |
| 2026-04-20 | 24.37x |
| 2026-04-17 | 24.13x |
| 2026-04-16 | 23.11x |
| 2026-04-15 | 23.23x |
| 2026-04-14 | 23.75x |
| 2026-04-13 | 23.81x |
| 2026-04-10 | 24.15x |
| 2026-04-09 | 24.76x |
| 2026-04-08 | 24.80x |
| 2026-04-07 | 23.81x |
| 2026-04-06 | 23.85x |
| 2026-04-02 | 23.48x |
| 2026-04-01 | 23.53x |
| 2026-03-31 | 23.69x |
| 2026-03-30 | 23.36x |
| 2026-03-27 | 23.49x |
| 2026-03-26 | 24.91x |
| 2026-03-25 | 25.19x |
| 2026-03-24 | 25.10x |
| 2026-03-23 | 24.86x |
| 2026-03-20 | 25.23x |
| 2026-03-19 | 25.35x |
| 2026-03-18 | 25.49x |
| 2026-03-17 | 25.37x |
| 2026-03-16 | 25.00x |
| 2026-03-13 | 24.23x |
| 2026-03-12 | 24.60x |
| 2026-03-11 | 24.99x |
| 2026-03-10 | 25.54x |
| 2026-03-09 | 25.89x |
| 2026-03-06 | 25.66x |
| 2026-03-05 | 26.62x |
| 2026-03-04 | 27.43x |
| 2026-03-03 | 27.50x |
| 2026-03-02 | 27.76x |
| 2026-02-27 | 27.63x |
| 2026-02-26 | 27.98x |
| 2026-02-25 | 27.53x |
| 2026-02-24 | 27.50x |
| 2026-02-23 | 27.57x |
| 2026-02-20 | 27.50x |
| 2026-02-19 | 27.20x |
| 2026-02-18 | 27.40x |
| 2026-02-17 | 26.52x |
| 2026-02-13 | 26.37x |
| 2026-02-12 | 24.54x |
| 2026-02-11 | 26.84x |
| 2026-02-10 | 26.85x |
| 2026-02-09 | 27.61x |
| 2026-02-06 | 27.54x |
| 2026-02-05 | 27.51x |
| 2026-02-04 | 27.87x |
| 2026-02-03 | 28.18x |
| 2026-02-02 | 28.52x |
| 2026-01-30 | 28.72x |
| 2026-01-29 | 29.09x |
| 2026-01-28 | 28.84x |
| 2026-01-27 | 28.96x |
| 2026-01-26 | 28.83x |
| 2026-01-23 | 28.65x |
| 2026-01-22 | 29.06x |
| 2026-01-21 | 28.36x |
| 2026-01-20 | 27.83x |
| 2026-01-16 | 27.38x |
| 2026-01-15 | 27.26x |
| 2026-01-14 | 27.44x |
| 2026-01-13 | 27.65x |
| 2026-01-12 | 27.93x |
| 2026-01-09 | 26.55x |
| 2026-01-08 | 26.95x |
| 2026-01-07 | 27.59x |
| 2026-01-06 | 27.51x |
| 2026-01-05 | 26.65x |
| 2026-01-02 | 26.22x |
| 2025-12-31 | 26.16x |
| 2025-12-30 | 26.42x |
| 2025-12-29 | 26.58x |
| 2025-12-26 | 26.62x |
| 2025-12-24 | 26.56x |
| 2025-12-23 | 26.35x |
| 2025-12-22 | 26.57x |
| 2025-12-19 | 26.04x |
| 2025-12-18 | 25.98x |
| 2025-12-17 | 25.92x |
| 2025-12-16 | 26.16x |
| 2025-12-15 | 25.91x |
| 2025-12-12 | 26.39x |
| 2025-12-11 | 27.15x |
| 2025-12-10 | 26.62x |
| 2025-12-09 | 26.14x |
| 2025-12-08 | 25.87x |
| 2025-12-05 | 25.82x |
| 2025-12-04 | 25.73x |
| 2025-12-03 | 25.58x |
| 2025-12-02 | 25.42x |
| 2025-12-01 | 25.07x |
| 2025-11-28 | 25.05x |
| 2025-11-26 | 24.69x |
| 2025-11-25 | 24.36x |
| 2025-11-24 | 24.56x |
| 2025-11-21 | 23.80x |
| 2025-11-20 | 23.11x |
| 2025-11-19 | 23.61x |
| 2025-11-18 | 23.78x |
| 2025-11-17 | 23.14x |
| 2025-11-14 | 22.97x |
| 2025-11-13 | 23.61x |
| 2025-11-12 | 23.57x |
| 2025-11-11 | 23.00x |
| 2025-11-10 | 21.74x |
| 2025-11-07 | 21.80x |
| 2025-11-06 | 22.96x |
| 2025-11-05 | 23.44x |
| 2025-11-04 | 24.17x |
| 2025-11-03 | 23.88x |
| 2025-10-31 | 23.03x |
| 2025-10-30 | 26.86x |
| 2025-10-29 | 51.25x |
| 2025-10-28 | 52.00x |
| 2025-10-27 | 53.00x |
| 2025-10-24 | 52.78x |
| 2025-10-23 | 53.31x |
| 2025-10-22 | 53.05x |
| 2025-10-21 | 52.37x |
| 2025-10-20 | 51.43x |
| 2025-10-17 | 50.12x |
| 2025-10-16 | 49.92x |
| 2025-10-15 | 49.27x |
| 2025-10-14 | 49.84x |
| 2025-10-13 | 49.12x |
| 2025-10-10 | 49.06x |
| 2025-10-09 | 51.17x |
| 2025-10-08 | 50.96x |
| 2025-10-07 | 49.71x |
| 2025-10-06 | 49.94x |
| 2025-10-03 | 50.44x |
| 2025-10-02 | 50.00x |
| 2025-10-01 | 49.74x |
| 2025-09-30 | 50.61x |
| 2025-09-29 | 50.02x |
| 2025-09-26 | 50.47x |
| 2025-09-25 | 51.33x |
| 2025-09-24 | 50.76x |
| 2025-09-23 | 51.26x |
| 2025-09-22 | 52.20x |
| 2025-09-19 | 50.72x |
| 2025-09-18 | 56.68x |
| 2025-09-17 | 57.15x |
| 2025-09-16 | 57.23x |
| 2025-09-15 | 56.54x |
| 2025-09-12 | 57.00x |
| 2025-09-11 | 56.84x |
| 2025-09-10 | 56.84x |
| 2025-09-09 | 58.55x |
| 2025-09-08 | 58.27x |
| 2025-09-05 | 60.06x |
| 2025-09-04 | 60.24x |
| 2025-09-03 | 58.93x |
| 2025-09-02 | 55.62x |
| 2025-08-29 | 56.37x |
| 2025-08-28 | 56.18x |
| 2025-08-27 | 57.11x |
| 2025-08-26 | 56.92x |
| 2025-08-25 | 56.81x |
| 2025-08-22 | 61.32x |
| 2025-08-21 | 60.14x |
| 2025-08-20 | 60.89x |
| 2025-08-19 | 60.34x |
| 2025-08-18 | 60.29x |
| 2025-08-15 | 60.38x |
| 2025-08-14 | 59.67x |
| 2025-08-13 | 59.67x |
| 2025-08-12 | 59.82x |
| 2025-08-11 | 58.16x |
| 2025-08-08 | 58.88x |
| 2025-08-07 | 57.12x |
| 2025-08-06 | 57.12x |
| 2025-08-05 | 56.45x |
| 2025-08-04 | 57.02x |
| 2025-08-01 | 59.18x |
| 2025-07-31 | 60.25x |
| 2025-07-30 | 66.18x |
| 2025-07-29 | 66.22x |
| 2025-07-28 | 66.35x |
| 2025-07-25 | 65.96x |
| 2025-07-24 | 64.37x |
| 2025-07-23 | 64.15x |
| 2025-07-22 | 63.22x |
| 2025-07-21 | 62.45x |
| 2025-07-18 | 62.35x |
| 2025-07-17 | 62.50x |
| 2025-07-16 | 62.52x |
| 2025-07-15 | 62.98x |
| 2025-07-14 | 63.37x |
| 2025-07-11 | 61.98x |
| 2025-07-10 | 63.46x |
| 2025-07-09 | 63.04x |
| 2025-07-08 | 62.26x |
| 2025-07-07 | 61.68x |
| 2025-07-03 | 61.67x |
| 2025-07-02 | 62.13x |
| 2025-07-01 | 62.13x |
| 2025-06-30 | 64.76x |
| 2025-06-27 | 64.08x |
| 2025-06-26 | 63.16x |
| 2025-06-25 | 62.91x |
| 2025-06-24 | 64.96x |
| 2025-06-23 | 59.48x |
| 2025-06-20 | 59.59x |
| 2025-06-18 | 60.31x |
| 2025-06-17 | 60.89x |
| 2025-06-16 | 61.72x |
| 2025-06-13 | 61.00x |
| 2025-06-12 | 61.61x |
| 2025-06-11 | 61.71x |
| 2025-06-10 | 63.01x |
| 2025-06-09 | 63.62x |
| 2025-06-06 | 64.32x |
| 2025-06-05 | 63.66x |
| 2025-06-04 | 63.57x |
| 2025-06-03 | 64.40x |
| 2025-06-02 | 63.50x |
| 2025-05-30 | 63.70x |
| 2025-05-29 | 63.04x |
Showing the most recent 260 of 2,707 data points. The chart above shows the full history.
Related Metrics
About DexCom, Inc.
DexCom, Inc. is a medical technology company primarily focused on innovating, developing, and marketing continuous glucose monitoring (CGM) systems. Operating across the United States and internationally, the firm provides its solutions for individuals managing diabetes as well as for healthcare practitioners. Its product portfolio features the DexCom G6, a comprehensive CGM system for diabetes management; the Dexcom Real-Time API, enabling authorized third-party developers to integrate live CGM data into their digital health applications; the Dexcom ONE, which aims to supersede traditional finger-prick blood glucose testing for treatment decisions; and Dexcom Share, a remote monitoring platform. The company is also developing the Dexcom G7, its next-generation CGM system. Furthermore, DexCom, Inc. has a licensing and collaboration agreement with Verily Life Sciences LLC and Verily Ireland Limited to advance blood-based or interstitial glucose monitoring products. The company directly sells its offerings to specialists such as endocrinologists, physicians, and diabetes educators. DexCom, Inc. was founded in 1999 and maintains its headquarters in San Diego, California.
- Sector
- Healthcare
- Industry
- Medical - Devices
- CEO
- Jacob Steven Leach